Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
9 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Shuttle Pharmaceuticals Holdings, Inc.’s names, not what it holds today.
Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 2 in 2023
Applications published
16
1 of them in 2025
Names they are printed under
2
a subsidiary
By yearGrantedApplications published
'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Shuttle Pharmaceuticals, Inc. a subsidiary
named as the applicant on its applications, in US
16 publishedShuttle Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jul 15, 2025 | 12,357,650 | Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
| Sep 3, 2024 | 12,077,515 | Selective histone deacetylase inhibitors for the treatment of human disease | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
| May 23, 2023 | 11,654,157 | Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
| Feb 21, 2023 | 11,584,733 | Selective histone deacetylase inhibitors for the treatment of human disease | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
| Aug 9, 2022 | 11,407,723 | Selective histone deacetylase inhibitors for the treatment of human disease | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
| Jun 15, 2021 | 11,034,667 | Selective histone deacetylase inhibitors for the treatment of human disease | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
| Aug 18, 2020 | 10,745,352 | Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
| Aug 4, 2020 | 10,730,834 | Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
| Nov 7, 2017 | 9,809,539 | Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 2, 2025 | 2025/0302857 | Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With Radiation | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
| Jul 11, 2024 | 2024/0226129 | Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorlylase Inhibitors In Combination With Radiation | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. · patent 12,357,650 granted from it |
| May 30, 2024 | 2024/0174630 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
| Sep 28, 2023 | 2023/0302034 | Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With Radiation | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
| Nov 17, 2022 | 2022/0363652 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. · patent 12,077,515 granted from it |
| Nov 3, 2022 | 2022/0348551 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. · patent 11,584,733 granted from it |
| Feb 24, 2022 | 2022/0055988 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
| Aug 26, 2021 | 2021/0261523 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. · patent 11,584,733 granted from it |
| Mar 18, 2021 | 2021/0078963 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. · patent 11,407,723 granted from it |
| Oct 8, 2020 | 2020/0317611 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | Pharmaceuticals | Shuttle Pharmaceuticals, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 3.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.